Pyxis Oncology, Inc.
PYXS
$1.06
$0.0151.44%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -21.79% | -47.28% | -12.89% | -17.38% | -31.22% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.98% | -6.90% | 10.06% | 0.17% | -54.73% |
| Operating Income | -6.98% | 6.90% | -10.06% | 77.02% | 54.73% |
| Income Before Tax | -141.94% | 8.01% | -8.80% | 83.08% | 56.80% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -128.06% | 8.01% | -8.80% | 83.08% | 56.80% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -128.06% | 8.01% | -8.80% | 83.08% | 56.80% |
| EBIT | -6.98% | 6.90% | -10.06% | 77.02% | 54.73% |
| EBITDA | -8.12% | 7.90% | -10.02% | 82.20% | 56.32% |
| EPS Basic | -65.61% | 37.39% | 30.95% | 88.33% | 66.19% |
| Normalized Basic EPS | 21.94% | 37.36% | 30.98% | 88.33% | 66.19% |
| EPS Diluted | -65.61% | 37.39% | 30.95% | 88.33% | 66.19% |
| Normalized Diluted EPS | 21.94% | 37.36% | 30.98% | 88.33% | 66.19% |
| Average Basic Shares Outstanding | 37.70% | 46.90% | 57.59% | 45.08% | 27.82% |
| Average Diluted Shares Outstanding | 37.70% | 46.90% | 57.59% | 45.08% | 27.82% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |